哌拉西林-他唑巴坦联合左氧氟沙星治疗重症社区获得性肺炎的疗效评价

Efficacy of piperacillin-tazobactam combined with levofloxacin for treatment of severe community acquired pneumonia

目的评价哌拉西林-他唑巴坦联合左氧氟沙星治疗重症社区获得性肺炎(SCAP)的疗效及安全性。方法回顾性分析哌拉西林-他唑巴坦联合左氧氟沙星治疗55例SCAP的临床疗效。结果临床总有效率为81.8%,平均疗程11.8天,细菌清除率达73.1%,不良反应轻微,主要包括:胃肠不适、皮疹、兴奋及白细胞减少等,均经停药或对症处理后缓解。结论哌拉西林-他唑巴坦联合左氧氟沙星治疗SCAP临床疗效好,安全性高,可作为治疗SCAP的经验性用药。

Objective To evaluate the efficacy and safety of piperacilli-tazobactam combined with levofloxacin for severe community acquired pneumonia （SCAP）. Methods The clinical efficacy data of 55 SCAP patients treated with piperacillin-tazobactam combined with levofloxacin were retrospectively analyzed. Results The total effective rate was 81.8% and the average course of treatment was 11.8 days. Bacterial clearance rate was 73.1%. The side-effect such as gastrointestinal upset, skin rash, leucopenia were light and could be releases after drug discontinuance or treating symp- tom. Conclusion Piperacillin-tazobactam combined with levofloxacin is effective and safe for SCAP and can be used as experiential antibiotics.